Treatment of Polyphasic Bursts and Cyclic Alternating Patterns in Sleep
The most effective treatment to reduce elevated cyclic alternating pattern (CAP) rates is cognitive behavioral therapy for insomnia (CBT-I), which should be initiated as first-line therapy, with zolpidem (10 mg) as a pharmacologic option that has demonstrated specific efficacy in reducing CAP rate when behavioral interventions are insufficient.
Understanding CAP and Its Clinical Significance
Cyclic alternating pattern represents organized arousal-related phasic events during NREM sleep that express sustained instability of the arousal level. Polyphasic bursts are one component of these arousal complexes. Elevated CAP rate (the ratio of CAP time to NREM sleep time) is a hallmark of insomnia and sleep fragmentation 1, 2. While healthy sleepers typically show CAP rates around 38-40%, patients with insomnia demonstrate significantly elevated rates of 60% or higher 1.
Treatment Algorithm
First-Line: Cognitive Behavioral Therapy for Insomnia (CBT-I)
Start with CBT-I as the initial intervention for all patients with elevated CAP rates associated with insomnia disorder 3, 4. This is a strong recommendation from the American College of Physicians based on moderate-quality evidence. CBT-I includes:
- Sleep restriction therapy - limiting time in bed to actual sleep time
- Stimulus control therapy - strengthening bed-sleep association
- Cognitive restructuring - addressing dysfunctional beliefs about sleep
- Relaxation training
- Sleep hygiene education (though not effective alone)
The 2016 ACP guideline explicitly recommends CBT-I as initial treatment before considering pharmacotherapy 4.
Second-Line: Pharmacologic Intervention
If CBT-I provides inadequate response, zolpidem 10 mg at bedtime has the strongest evidence for specifically reducing CAP rate 1, 5, 6. Research demonstrates:
- CAP rate reduction from 62% to 27% in insomniacs (a 56% decrease) 1
- Sustained efficacy over 4 weeks of continuous use without tolerance 5
- Restoration of physiological CAP amounts while maintaining normal sleep architecture 6
- Protection against environmental perturbations that increase CAP 6
The 2008 AASM guideline supports short/intermediate-acting benzodiazepine receptor agonists (including zolpidem) as first-line pharmacotherapy when medication is indicated 7.
Alternative Pharmacologic Options
If zolpidem is contraindicated or ineffective, consider 8, 4, 7:
- Other benzodiazepine receptor agonists: eszopiclone, zaleplon, temazepam
- Ramelteon (melatonin receptor agonist)
- Doxepin (low-dose sedating antidepressant)
- Suvorexant (orexin receptor antagonist)
Combined Approach
Pharmacotherapy should be supplemented with behavioral and cognitive therapies whenever possible 7. This consensus recommendation recognizes that combining treatments may provide superior outcomes, though the evidence base is limited.
Important Clinical Considerations
Monitoring Treatment Response
- Track CAP parameters if polysomnography is available - CAP rate is more sensitive than traditional sleep parameters for detecting treatment efficacy 1, 2
- Use sleep diaries and validated questionnaires (Insomnia Severity Index, Pittsburgh Sleep Quality Index) 3
- Reassess every few weeks until stable, then every 6 months due to high relapse rates 7
Common Pitfalls to Avoid
Do not use sleep hygiene education alone - it is ineffective as monotherapy and must be combined with other interventions 9, 7
Avoid long-term benzodiazepines without behavioral therapy - the 2008 AASM guideline emphasizes supplementing pharmacotherapy with CBT-I 7
Do not assume normal polysomnography rules out pathology - traditional sleep parameters may appear normal while CAP rate remains significantly elevated 1
Recognize that polyphasic sleep schedules themselves can be pathologic - radically restricted polyphasic sleep patterns abolish growth hormone release and are not sustainable 10
Special Populations
For patients with comorbid conditions affecting CAP 11:
- Sleep apnea: Treat underlying breathing disorder first
- Epilepsy: Surgical treatment of temporal lobe epilepsy can reduce CAP rate 12
- Depression/anxiety: Consider sedating antidepressants (trazodone, doxepin, mirtazapine) as second-line agents 7
Duration of Treatment
- CBT-I effects are durable and should be maintained long-term 3
- Pharmacotherapy with zolpidem maintains efficacy for at least 4 weeks without significant tolerance to CAP-reducing effects 5
- After medication discontinuation, gradual tapering is recommended 5
The evidence strongly supports a stepped approach: initiate CBT-I, add zolpidem if needed, and maintain combined therapy with regular monitoring of both subjective sleep quality and objective measures when available.